Bacil Pharma Ltd
Bacil Pharma Ltd (BACPHAR) is scheduled to report results on 14 Oct 2026. Bacil Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0 crore and net profit of ₹-0.02 crore. The stock last traded at ₹27, a market capitalisation of ₹38.8 crore, on a P/E of 59.6. Over the past 52 weeks the stock has ranged between ₹10.6 and ₹61.8. Figures are as of 6 Oct 2026 and are not real time.
Bacil Pharma Ltd share price and key metrics
- Current price
- ₹27
- Market cap
- ₹38.8 cr
- Stock P/E
- 59.6
- Book value
- ₹17.3
- ROE
- 6.21%
- ROCE
- 3.93%
- Dividend yield
- 0.00%
- 52w high / low
- 61.8/10.6
Metrics as of 6 Oct 2026. Not real time.
Track Bacil Pharma Ltd
Cruxal reads every Bacil Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Bacil Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- 38%
- 5 Years
- 77%
- 3 Years
- 131%
- TTM
- -41%
- 10 Years
- 14%
- 5 Years
- 42%
- 3 Years
- 43%
- 1 Year
- -41%
- 10 Years
- 0%
- 5 Years
- 2%
- 3 Years
- 3%
- Last Year
- 6%
Bacil Pharma Ltd quarterly results
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.07 | 0.06 | 0.07 | 0.11 | 0.03 | 0.02 | 0.07 | 0.02 |
| Operating profit | -0.07 | -0.06 | -0.07 | -0.11 | -0.03 | -0.02 | -0.07 | -0.02 |
| OPM % | — | — | — | — | — | — | — | — |
| Other income | 0.56 | 0 | 0.09 | 1 | 0.05 | 0.06 | 0.11 | 0.09 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.49 | -0.06 | 0.02 | 0.89 | 0.02 | 0.04 | 0.04 | 0.07 |
| Tax % | 0.00% | 0.00% | 0.00% | 24.72% | 0.00% | 0.00% | -1,450.00% | 114.29% |
| Net profit | 0.48 | -0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | -0.02 |
| EPS (₹) | 0.81 | -0.10 | 0.01 | 0.47 | 0.01 | 0.03 | 0.43 | -0.01 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bacil Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.25 | -0.14 |
| OPM % | — | — | — | — | — | — | — | — | — | — | — |
| Net profit | 0 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.1 | -0.06 | 0.4 | 1.56 | 0.65 |
| EPS (₹) | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.09 | 0.46 |
TTM is the trailing twelve months to the most recent quarter.
Bacil Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 | 13.97 |
| Reserves | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.30 | -5.43 | -5.31 | 11.46 | 10.84 |
| Borrowings | 0.31 | 0.00 | 0.10 | 0.17 | 0.18 | 0.03 | 0.02 | 0.10 | 0.16 | 0.00 |
| Other liabilities | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 | 2.58 |
| Total liabilities | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| Fixed assets | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 | 24.24 |
| Other assets | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 | 3.15 |
| Total assets | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
As reported by the company. Total assets equal total liabilities by construction.
Bacil Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.00 | 1.44 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 |
| Cash from investing | 0.02 | -1.20 | 0.28 | 0.39 | 0.53 | 3.81 | -0.12 | 0.08 | 0.34 | -2.38 |
| Cash from financing | 0.00 | 0.00 | -0.16 | -0.06 | -0.07 | 0.33 | 0.06 | -0.06 | 2.08 | -0.62 |
| Net cash flow | 0.02 | 0.23 | -0.18 | -0.05 | 0.06 | 0.13 | -0.20 | 0.01 | 2.82 | -2.29 |
| Free cash flow | 0.00 | 1.14 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 |
| CFO / operating profit | 0% | -497% | 115% | 211% | 250% | 2,506% | 88% | 0% | -160% | -284% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Bacil Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% | 3.93% |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Bacil Pharma Ltd shareholding pattern
Promoters held 0.00% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 20.71% | 10.60% | 0.20% | 0.20% | 0.08% | 0.08% | 0.00% | 0.00% |
| Public | 79.30% | 89.39% | 99.80% | 99.80% | 99.92% | 99.92% | 100.00% | 100.00% |
| No. of shareholders | 6,902 | 7,461 | 7,638 | 7,532 | 7,431 | 7,431 | 7,226 | 7,326 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Bacil Pharma Ltd’s next results date?
Bacil Pharma Ltd’s next results are scheduled for 14 Oct 2026.
- Board meetingConsideration and approval of unaudited financial results for half-yearly and quarterly ended 30th September 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Bacil Pharma Ltd corporate filings
- Bacil Pharma Limited announces resignation of Whole-Time Company Secretary effective 8 October 2026, with ongoing appointment processCompany Updatelow impact
Cruxal's analysis: Bacil Pharma Limited has formally announced the resignation of Mr. Dikshant Singh Panwar…
Read the full analysis - Bacil Pharma Limited schedules Board meeting on 14th October 2026 to consider unaudited financial results for half-year ended 30th September 2026Board Meetinglow impact
Cruxal's analysis: Bacil Pharma Limited has announced a Board meeting scheduled for 14th October 2026 to…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Bacil Pharma Limited concludes 39th AGM with approval for leadership transition and capital restructuringAGM/EGMlow impact
Cruxal's analysis: Bacil Pharma Limited has successfully concluded its 39th Annual General Meeting, where…
Read the full analysis - Bacil Pharma Limited Announces Proceedings of 39th Annual General Meeting and Leadership RestructuringAGM/EGMmedium impact
Cruxal's analysis: Bacil Pharma Limited has concluded its 39th Annual General Meeting, where shareholders…
Read the full analysis - Bacil Pharma Ltd releases Annual Report for FY 2025-2026Otherslow impact
Cruxal's analysis: Bacil Pharma Ltd has filed its Annual Report for the financial year 2025-2026. The…
Read the full analysis - Bacil Pharma Limited Announces 39th AGM, Management Restructuring, and Capital Expansion PlanAGM/EGMmedium impact
Cruxal's analysis: Bacil Pharma Limited has scheduled its 39th Annual General Meeting for September 23…
Read the full analysis - Bacil Pharma Ltd announces book closure for Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Bacil Pharma Ltd has issued an intimation regarding the closure of its register of…
Read the full analysis - Bacil Pharma Limited Announces 39th AGM, Management Restructuring, and Capital Expansion PlanBoard Meetingmedium impact
Cruxal's analysis: Bacil Pharma Limited has scheduled its 39th Annual General Meeting for September 23…
Read the full analysis - Bacil Pharma Limited schedules Board Meeting for 29th August, 2026 to finalize 39th AGM detailsBoard Meetinglow impact
Cruxal's analysis: Bacil Pharma Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis - Bacil Pharma Limited announces board expansion with appointment of two new directorsBoard Meetinglow impact
Cruxal's analysis: Bacil Pharma Limited has appointed Mr. Mahesh Singh as an Additional Independent Director…
Read the full analysis - Bacil Pharma Limited schedules Board Meeting for August 25, 2026, to discuss appointment of directorsBoard Meetinglow impact
Cruxal's analysis: Bacil Pharma Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis - Bacil Pharma Limited Reports Q1 FY2027 Financial Results with Nil Revenue from OperationsBoard Meetinglow impact
Cruxal's analysis: Bacil Pharma Limited reported nil revenue from operations for the quarter ended 30th June…
Read the full analysis - Bacil Pharma Limited schedules Board Meeting for August 12, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Bacil Pharma Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.